000 nab a22 7a 4500
999 _c15962
_d15962
003 PC15962
005 20210304100922.0
008 200602b xxu||||| |||| 00| 0 eng d
040 _cH12O
041 _aeng
100 _983
_aMorales Ruiz, Enrique
_eNefrología
100 _9417
_aGutiérrez Martínez, Eduardo
_eNefrología
245 0 0 _aCinacalcet for hypercalcaemic secondary hyperparathyroidism after renal transplantation: a multicentre, retrospective, 3-year study.
_h[artículo]
260 _bNephrology (Carlton, Vic.),
_c2014
300 _a19(2):84-93.
500 _aFormato Vancouver: Torregrosa JV, Morales E, Díaz JM, Crespo J, Bravo J, Gómez G et al; CINAREN Study Group. Cinacalcet for hypercalcaemic secondary hyperparathyroidism after renal transplantation: a multicentre, retrospective, 3-year study. Nephrology (Carlton). 2014 Feb;19(2):84-93.
501 _aPMID: 24428216
504 _aContiene 47 referencias
520 _aAims: Our aim was to evaluate the long-term effect of cinacalcet in patients with hypercalcaemic secondary hyperparathyroidism (SHPT) after renal transplantation (RT) in order to expand real-world data in this population. Methods: We performed a multicentre, observational, retrospective study in 17 renal transplant units from Spain. We collected data from renal recipients with hypercalcaemic (calcium >10.2 mg/dL) SHPT (intact parathyroid hormone (iPTH) > 120 pg/mL) who initiated cinacalcet in the clinical practice. Results: We included 193 patients with a mean (standard deviation (SD)) age of 52 (12) years, 58% men. Cinacalcet treatment was initiated at a median of 20 months after RT (median dose 30 mg/day). Mean calcium levels decreased from a mean (SD) of 11.1 (0.6) at baseline to 10.1 (0.8) at 6 months (9.0% reduction, P < 0.0001). Median iPTH was reduced by 23.0% at 6 months (P = 0.0005) and mean phosphorus levels increased by 11.1% (P < 0.0001). The effects were maintained up to 3-years. No changes were observed in renal function or anticalcineurin drug levels. Only 4.1% of patients discontinued cinacalcet due to intolerance and 1.0% due to lack of efficacy. Conclusions: In renal transplant patients with hypercalcaemic SHPT, cinacalcet controlled serum calcium, iPTH and phosphorus levels up to 3 years. Tolerability was good.
710 _986
_aServicio de Nefrología
856 _uhttp://pc-h12o-es.m-hdoct.a17.csinet.es/pdf/pc/1/pc15962.pdf
_ySolicitar documento
942 _2ddc
_cART
_n0